top of page

Game-changing treatments for retinal neurodegenerative
diseases

Diabetic retinopathy

Who we are

D-Sight is a spin-off company from Vall d’Hebron Institute of Research (VHIR) lead by an experienced and committed team dedicated to the discovery and development of new innovative treatments for neurodegenerative diseases of the retina.

WHO WE ARE

D-Sight is a spin-off company from Vall d’Hebron Institute of Research (VHIR) lead by an experienced and committed team dedicated to the discovery and development of new innovative treatments for neurodegenerative diseases of the retina.

Sitagliptin eyedrops

Improving the quality of life of diabetic patients

We have developed a first-in-class solution for the prevention and treatment of early stages of diabetic retinopathy.

 

D-Sight addresses a wide-spread unmet medical need with a cost-effective, non-invasive and safe treatment, which also prevents side-effects and limitations associated to current standard-of-care therapies.

An early treatment for the leading cause of
preventable blindness in working-age population

643M

ADULTS SUFFERING DIABETES WORLDWIDE
BY 2030

60%

TYPE 2 DIABETIC PATIENTS (AND NEARLY ALL TYPE 1) DEVELOPT DIABETIC RETINOPATHY

185M

ADULTS SUFFERING DIABETIC RETINOPATHY IN WORKING-AGE WORLDWIDE

ojo.png

Team members

D-Sight is founded and lead by world leaders in diabetic retinopathy, diabetes and other neurodegenerative diseases linked to the retina.

FOUNDERS

Carla Maté Goldar
Carla Maté Goldar

CEO

Carla Maté Goldar

  • LinkedIn
Rafael-Simo_0_edited_edited.jpg
Rafael Simó Canonge

CMO

Rafael Simó Canonge

  • LinkedIn
Cristina-Hernandez-DSight_edited.jpg
Cristina-Hernandez

CSO

Cristina Hernández Pascual

  • LinkedIn

SUPPORTED BY

campus_vhir_digital (rgb)-NEGATIU.png
logo ministerio inn.png
logo isciii.png
Logo PRTR vertical_COLOR.png
logo Clave transparente.png
DIGITAL_EIT Health logo_Landscape Full Colour.png

CONTACT US

We'd love to hear from you

bottom of page